# APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

> clinical trial · VERIFIED · 2026-08-05

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Pancreatic Acinar Cell Carcinoma

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT04858334

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.